Clik here to view.
Astellas Reports First Quarter Financial Results of FY2016
TOKYO Astellas Pharma Inc. (TOKYO:4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for the first quarter of fiscal year 2016 ending March 31, 2017...
View ArticleClik here to view.
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first quarter results and confidence in Management Guidance • Underlying revenue grew +9.1%, driven by a +15.3% increase...
View ArticleClik here to view.
武田薬品：2016年度第1四半期の連結業績について力強いスタートで年間マネジメントガイダンスを堅持
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 2016年度第1四半期（4-6月期）の力強い業績により、年間マネジメントガイダンスを堅持...
View ArticleClik here to view.
武田公布2016财年第一季度业绩，财年开局喜人，有信心实现管理层指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(TOKYO:4502)： 强劲的第一季度业绩，有信心实现管理层指引 • 基础营收增长+9.1%，得益于武田增长引擎（胃肠药、肿瘤药、CNS和新兴市场）+15.3%的增长。（根据报告的营收下降-2.8%，至4,340亿日元，归咎于撤资和货币影响） •...
View ArticleClik here to view.
Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate...
LONDON Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 global licensing, co-development, and commercialisation agreement (the “2011 Agreement”) regarding...
View ArticleClik here to view.
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the Phase 3 ALCANZA clinical...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the...
LONDON Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market,...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place...
View ArticleClik here to view.
武田与Seattle Genetics发布ADCETRIS® (Brentuximab...
华盛顿州博瑟尔、马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)与Seattle Genetics, Inc. (NASDAQ:SGEN)今天宣布，评估ADCETRIS (brentuximab...
View ArticleClik here to view.
武田薬品とシアトル・ジェネティクスがCD30発現皮膚T細胞リンパ腫でアドセトリス（ブレンツキシマブ・ベドチン）を検討する第3相ALCANZA臨床試験の良好...
米ワシントン州ボセル & マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Nativis, Inc. Enters into Evaluation Agreement with Major Japan-Based...
SEATTLE Nativis, Inc., a clinical stage life sciences company developing non-invasive, medical device therapies for cancers and other serious diseases, today announced that it has entered into an...
View ArticleClik here to view.
NCCNガイドラインでオプチューンが初発膠芽腫の標準的治療の選択肢として推奨される
ジャージー島セントへリア （ビジネスワイヤ） — ノボキュア社（NASDAQ: NVCR）は本日、全米総合がん情報ネットワーク（NCCN）が中枢神経系がんの腫瘍診療ガイドライン（NCCNガイドライン）で、オプチューンを初発膠芽腫（GBM）の標準的治療の選択肢として推奨したと発表しました。...
View ArticleClik here to view.
Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced Takeda Canada has received approval from Health Canada for NINLARO™ (ixazomib) capsules in...
View ArticleClik here to view.
CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory...
SHANGHAI Boehringer Ingelheim and CANbridge Life Sciences announced that both parties have signed an agreement for the manufacture of CAN-017, an ErbB3 (HER3) inhibitory antibody to treat esophageal...
View ArticleClik here to view.
ピラマル・エンタープライゼズが高活性原薬（HPAPI）の米国CDMOアッシュ・スティーブンスを買収する契約を締結
印ムンバイ （ビジネスワイヤ） — ピラマル・エンタープライゼズ・リミテッド (PEL、NSE: PEL、BSE:...
View ArticleClik here to view.
Takeda Announces Bold, New Access to Medicines Strategy
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced the launch of a bold, new Access to Medicines (AtM) strategy, aimed at increasing access to its innovative and...
View ArticleClik here to view.
武田薬品: 医薬品アクセス（Access to Medicines）に関する新たな取り組みについて
大阪 （ビジネスワイヤ） — 当社は、このたび、アンメットメディカルニーズの高い患者さんを対象に、生命を救う可能性のある当社の革新的な医薬品に対するアクセスを改善することを目的として、医薬品アクセス（Access to...
View ArticleClik here to view.
SciBase: New Study: Swedish Nevisense Can Reduce Follow-up Visits by Half for...
STOCKHOLM SciBase (STO:SCIB) A new Australian study, using the Swedish instrument Nevisense, showed it is possible to reduce the number of cases that require digital dermoscopy follow-up by almost...
View ArticleClik here to view.
ZRG Partners Releases Q2 2016 Global Life Sciences Hiring Index
ROCHELLE PARK, N.J. ZRG Partners has announced the findings for the second quarter Global Life Sciences Hiring Index. 2016 has shown an increase in hiring demand consistently, posting 50% higher...
View ArticleClik here to view.
武田发布宏伟的全新药品获取战略
日本大阪 (美国商业资讯) — 武田药品工业株式会社(TOKYO:4502)今天宣布启动一项宏伟的全新药品获取(Access to Medicines, AtM)战略，旨在使面临部分最紧迫的未获满足医疗需求的患者增加获取有望挽救生命的武田创新药品。数十年来，该公司依据地区性的需求，已在世界许多地方提供产品、经费和获取。新的AtM战略以此为基础，专注于面临最紧迫的未获满足需求的地区和治疗领域。...
View Article